Nelson Advisors: Agentic AI, Ambient Voice Technology, and the European Clinical Frontier: Where the 2027 Debates Will Be Fought
Agentic AI, Ambient Voice Technology and the European Clinical Frontier: Where the 2027 Debates Will Be Fought
The European healthcare sector has arrived at a structural inflection point in clinical documentation and ambient intelligence. Ambient Voice Technology (AVT), which initially commanded premium software valuations by converting clinician patient dialogue into structured clinical summaries, is succumbing to rapid technological commoditisation. Foundational acoustic modelling and large language model (LLM) summarisation capabilities have matured into accessible utilities, eroding the pricing power of vendors that merely generate passive administrative records.
In response, the technological frontier has pivoted toward agentic clinical architectures: systems capable of moving beyond observational note drafting to autonomously execute clinical actions, stage computerised physician order entry (CPOE) queues, query diagnostic histories, formulate treatment plans, and interact bidirectionally with electronic health record (EHR) environments.
This technological transition shatters the long-standing regulatory defense used by first-generation ambient scribe vendors, who argued that transcription software is an administrative productivity tool exempt from medical device classification because a human clinician signs off on the final text.
By shifting from passive transcription to autonomous clinical execution, these systems fall squarely into the scope of active medical device legislation.
Over the next twelve to twenty-four months, the definitive regulatory, legal, and clinical safety debates across the United Kingdom and the European Union will not centre on speech to text accuracy metrics or user-interface ergonomics. Instead, they will be fought over clinical liability distribution, autonomous execution thresholds within EHRs, dynamic lifecycle safety assurance and the operational boundaries of Predetermined Change Control Plans (PCCPs).
The primary regulatory milestone of this cycle will occur in 2027: the formal market certification, under UKCA Class IIa or EU Medical Device Regulation (EU MDR) Class IIa, of the first fully agentic clinical product capable of independently placing orders and initiating clinical tasks, with the UK Medicines and Healthcare products Regulatory Agency (MHRA) AI Airlock Phase 3 guidance on predetermined change control plans serving as the catalyst.
The Paradigm Shift: From Passive Documentation to Agentic Orchestration
First generation ambient clinical documentation platforms functioned as unidirectional open loop systems. They captured ambient audio during consultations, processed speech through specialised automatic speech recognition engines, and deployed generative models to draft Subjective, Objective, Assessment and Plan (SOAP) notes.
Vendors maintained that their products did not constitute Software as a Medical Device (SaMD) because they claimed no diagnostic or therapeutic purpose, framing the clinician as an infallible "human-in-the-loop" who verified the text before committing it to the medical record.
That posture is no longer viable. Passive summarization cannot sustain enterprise software margins when foundation model providers offer medical transcription and structuring at near-zero marginal cost. Enterprise health systems increasingly demand software that addresses administrative bottlenecks directly inside the EHR workflow.
Consequently, venture capital and engineering efforts have shifted to the agentic workflow layer: autonomous software capable of synthesising clinical dialogue, understanding diagnostic intent, interrogating patient history, and executing multi-step clinical tasks across hospital information systems.
Operational Dimension | Generation 1: Passive Ambient Scribing | Generation 2: Agentic Clinical Orchestration |
Primary System Objective | Passive speech transcription and structured narrative SOAP note synthesis. | Contextual clinical reasoning, computerized physician order entry (CPOE), and autonomous care pathway execution. |
EHR Interoperability | Unidirectional text insertion; clipboard pasting or basic note-field write-back. | Deep, bidirectional integration via FHIR APIs; reading historical charts and writing active diagnostic, lab, and prescription orders. |
Supervisory Model | Post-encounter manual review and textual editing of narrative notes. | Tiered agency; exception-based clinician authorization of pre-staged diagnostic and therapeutic action queues. |
Regulatory Classification | Historically self-declared Class I (now disputed) or non-device software. | Minimum Class IIa Software as a Medical Device (SaMD) under EU MDR and UK MDR. |
Algorithmic Architecture | Static prompt engineering on frozen, commercial foundation LLMs. | Multi-agent frameworks, dynamic tool-calling, retrieval-augmented generation (RAG), and continuously monitored adaptive learning models. |
When an AI system transitions from summarising a conversation to selecting an International Classification of Diseases (ICD) code, determining a drug dosage against renal function curves retrieved from historical lab panels, or generating an active prescription, it crosses the threshold into clinical decision support and direct medical intervention.
The legal fiction that the clinician serves as an absolute safeguard collapses in real-world clinical environments characterized by cognitive overload, severe time constraints and automation bias.
By enabling systems to initiate clinical actions, vendors abandon the safe harbour of administrative transcription and enter the strict regulatory regimes governing active medical devices.
The European Regulatory Framework: EU MDR Rule 11 and the Swedish Precedent
Within the European Union, the regulatory ambiguity surrounding clinical documentation software has been resolved through regulatory enforcement and judicial interpretation of Regulation (EU) 2017/745 (EU MDR). Software qualification and classification under EU MDR are determined by intended clinical purpose rather than commercial branding or technical deployment models. Under Annex VIII, Rule 11, software intended to provide information used to make decisions with diagnostic or therapeutic purposes is classified as Class IIa at a minimum.
Historically, vendors sought shelter under sub-rule 11(c), a residual clause that permits Class I status for software that does not influence clinical decisions or monitor physiological processes. This defence was systematically dismantled on 27 May 2026, when Sweden’s Medical Products Agency (Läkemedelsverket) published the findings of its market surveillance inspection under the AI Ambient Scribe Focus Initiative.
The Swedish regulator issued a binding nonconformity against the manufacturer of an ambient clinical scribe, declaring that classifying an AI medical documentation system as a Class I medical device is fundamentally incompatible with EU MDR. The MPA established that Class IIa under sub-rule 11(a) represents the absolute minimum regulatory floor for ambient clinical AI.
The legal foundation of this decision rests on the Continued Care Process Doctrine. Innovators argued that because the treating clinician is physically present in the examination room and makes the actual clinical determination during the consultation, the AI scribe does not make or influence a clinical decision.
The MPA rejected this reasoning, demonstrating that medical notes are not ephemeral records; they are durable clinical instruments designed to inform clinical decisions throughout the patient's ongoing care. Subsequent physicians, triage nurses, and covering clinicians rely directly on the AI-generated record to determine future therapies, assess disease trajectory, and adjust medications.
To solidify this determination, the regulator examined the manufacturer’s internal risk management documentation compiled under ISO 14971. The manufacturer's hazard log identified clinical failure pathways, including delayed or missed diagnoses resulting from misheard clinical statements, hallucinated negative findings, or omitted symptoms.
The MPA ruled that a manufacturer cannot identify severe clinical harm pathways within its confidential risk management files while simultaneously asserting to European competent authorities that its software does not inform clinical decisions.
Furthermore, the MPA clarified that clinician sign-off is merely a human-in-the-loop risk control measure, and under established EU medical device law, a risk control cannot be cited to downgrade the inherent risk classification of a device.
This ruling sets a pan-European precedent that exposes every ambient AI scribe and agentic workflow platform operating in the EU to regulatory enforcement.
To achieve Class IIa compliance, manufacturers must abandon self-certification and submit their software to an independent Notified Body, requiring an audited ISO 13485 Quality Management System (QMS), software lifecycle validation under EN IEC 62304 (typically Class B), cybersecurity risk management under EN IEC 81001-5-1 and an extensive Clinical Evaluation Report (CER) proving accuracy and clinical safety across multiple medical specialties.
This baseline is reinforced by the European Union AI Act (Regulation EU 2024/1689), which entered its high-risk enforcement phase in August 2026. Under Article 6 of the AI Act, an AI system that is a medical device covered by EU MDR or is a safety component of one and is required to undergo third-party conformity assessment by a Notified Body is classified as a High-Risk AI System.
This subjects agentic clinical tools to dual regulatory oversight: Notified Bodies assess medical device conformity under MDR Annex IX while simultaneously auditing technical compliance with the AI Act’s mandates on high-quality training and validation datasets, algorithmic transparency, automated continuous event-logging and human oversight architectures.
The UK Vanguard: MHRA AI Airlock Phase 3 and Predetermined Change Control Plans
While the European Union enforces a strict compliance baseline through Notified Body review under Rule 11, the United Kingdom is building an adaptive regulatory model designed to resolve the contradiction between static medical device approvals and continuously evolving AI systems. Traditional medical device frameworks were designed for fixed software packages; any substantive change to algorithmic weights, diagnostic thresholds, or feature scope required formal regulatory change notifications or de novo approvals.
In agentic clinical software, where models must continuously integrate real-world clinical feedback, adapt to local terminology, and refine tool-calling APIs, a static approval model paralyses development and deployment.
The Denniston Commission and the Policy Transformation
In September 2025, the MHRA established the National Commission into the Regulation of AI in Healthcare, chaired by Professor Alastair Denniston. The Commission published its definitive report on 10 September 2026, delivering 44 recommendations to modernise health technology regulation.
The Commission observed that the legacy UK Medical Devices Regulations 2002 lacked the lifecycle oversight mechanisms required to govern adaptive algorithmic systems, recommending that the UK move away from static, point in time market approvals toward continuous post-market assurance and risk-proportionate qualification.
On 6th October 2026, the UK Government announced that it had accepted all 44 recommendations in full. Health Innovation Minister James Frith and MHRA Chief Executive Lawrence Tallon committed the UK to a clear regulatory timetable:
The MHRA committed to issuing draft guidance by December 2026 establishing an adaptive framework for managing modifications and updates to AI-enabled medical devices throughout their clinical lifecycle.
The government scheduled a formal public consultation for early 2027 regarding secondary legislation to redefine device qualification and risk classification, addressing the historical loopholes of Class I self-certification and formalising staged market authorisation pathways ("L-plates") to allow supervised NHS clinical deployment while generating real-world safety data.
The delivery of a cross-government implementation roadmap in Spring 2027, backed by the Department of Health and Social Care (DHSC) and the Regulatory Innovation Office (RIO) chaired by Lord Willetts.
Concurrently with this policy announcement, the MHRA officially opened applications for Phase 3 of its AI Airlock regulatory sandbox on 6 October 2026, backed by £3.6 million in dedicated funding extending through April 2029.
While the initial AI Airlock pilot (April 2024 to April 2025) examined four early generative technologies, and Phase 2 (October 2025 to May 2026) evaluated seven candidates tackling intended use boundary changes and hallucination mitigations, Phase 3 focuses entirely on post-market surveillance (PMS) and continuous lifecycle oversight in real-world clinical deployments.
Predetermined Change Control Plans as the Regulatory Linchpin
The technical mechanism driving this transformation is the Predetermined Change Control Plan (PCCP). Developed through international harmonization between the MHRA, the U.S. FDA, and Health Canada, a PCCP allows an AI manufacturer to establish a pre-authorised envelope of anticipated model iterations, retraining protocols and intended-use expansions directly within its initial regulatory dossier.
For an agentic clinical product, a certified PCCP establishes an authorised operational boundary. Within this envelope, model capabilities can expand from basic note drafting to order generation, multi-specialty vocabulary integration and programmatic EHR interactions without requiring repeated UKCA pre-market submissions.
The MHRA’s forthcoming December 2026 guidance operationalises these principles, providing the regulatory foundation that will enable the first agentic clinical products to secure Class IIa certification in 2027.
The viability of this pathway was established by the regulatory trajectory of UK ambient intelligence developer TORTUS. Originally registering an ambient scribe tool as a Class I medical device in November 2024, TORTUS participated in Phase 2 of the MHRA AI Airlock program to navigate intended-use extensions and validate its proprietary hallucination-mitigation architecture, known as "The Shell".
In June 2026, TORTUS secured the world's first UKCA Class IIa medical device certification for an ambient voice technology platform.
TORTUS's subsequent deployments across 3,500 primary care practices via X-on Health telephony, alongside native ambient EHR integrations with Epic and Cerner at Somerset NHS Foundation Trust and Royal Devon, proved that formal Class IIa certification accelerates enterprise procurement across the NHS.
Clinical Safety Governance: The DCB0129 and DCB0160 Mandate
In the United Kingdom, medical device registration via UKCA or EU MDR CE-marking is necessary but insufficient for health system procurement. The Health and Social Care Act 2012 mandates compliance with two interrelated clinical risk management standards: DCB0129 for health IT manufacturers and DCB0160 for adopting healthcare organisations.
These standards create a mandatory clinical safety framework: the manufacturer's internal engineering risk file (DCB0129) must directly inform the local health authority’s clinical deployment safety case (DCB0160).
When software evolves from passive transcription to agentic execution, clinical risk changes from passive documentation inaccuracies to active intervention hazards.
Both DCB0129 and DCB0160 require the appointment of a Clinical Safety Officer (CSO), a registered healthcare professional trained in health IT risk management.
Under DCB0129, the vendor's CSO must hold executive authority to halt software releases if clinical risks exceed acceptable levels, while the deploying organisation's CSO under DCB0160 must assess whether site-specific clinical workflows can absorb the technology without introducing unmitigated patient risk.
Hazard Identifier | Passive Documentation Hazard Profile | Agentic AI Execution Hazard Profile | Mandatory DCB0129/DCB0160 Safety Mitigations |
Transcription and Semantic Drift | Spoken clinical narrative misheard, introducing minor factual errors into encounter notes. | Phonetic misinterpretation translates into an incorrect drug molecule, dose, or frequency staged in a live CPOE queue. | Dual-token semantic verification, programmatic confirmation against patient drug history, and mandatory dose-range cross-checks. |
Generative Hallucination | System generates plausible but fabricated clinical findings within a physical exam summary. | Agentic engine hallucinates a clinical indication, automatically drafting inappropriate lab orders or diagnostic imaging. | Architectural retrieval-augmented generation (RAG) bounds, strict prompt grounding against consultation audio, and output gating. |
Context and Entity Contamination | Patient discusses a relative’s illness; software records the condition under patient's active medical history. | System misattributes familial pathology to the patient, automatically staging invasive diagnostic workups or medication regimens. | Multi-speaker acoustic diarization, contextual entity resolution, and explicit clinician assertion verification prior to order generation. |
Automation Bias and Clinician Fatigue | Clinician skims and approves an extensive narrative note without thoroughly reading each line. | Clinician rapidly bulk-approves staged CPOE order sets at the end of a shift without verifying individual indications. | Tiered agency interfaces, forced friction requiring active authentication for high-risk actions, and randomized confirmation prompts. |
Asynchronous EHR Desynchronization | Draft note fails to save to the database during an API timeout, resulting in lost narrative documentation. | Clinical note commits to the EHR, but an asynchronous network timeout drops an active laboratory or medication command. | Idempotent transaction verification, two-phase commit protocols across FHIR APIs, and automated transactional rollback alerts. |
Governing these failure modes requires replacing binary human-in-the-loop models with tiered agency architectures.
Under tiered agency, low-risk administrative actions (such as populating follow-up intervals or drafting routine correspondence) may execute with passive notification, whereas high-risk clinical actions (including staging computerised prescriptions, ordering ionising radiation imaging, or triggering urgent referrals) require explicit, authenticated clinician confirmation before hitting the EHR database.
Deploying NHS Trusts cannot accept an agentic tool without a comprehensive DCB0160 clinical safety case that evaluates site-specific network topologies, user training, and audit trails.
Market Dynamics: The Agentic Workflow Layer as a Competitive Moat
The intersection of generative AI capabilities with European regulatory enforcement has transformed health-tech venture dynamics.
Between 2022 and 2024, venture investment flowed heavily into ambient scribe startups operating on standard software-as-a-service (SaaS) business models, characterised by rapid viral deployment and minimal regulatory oversight.
By late 2026, this approach has hit structural barriers. Unregulated tools face procurement moratoria across NHS Integrated Care Boards and European regional health authorities due to patient safety concerns, data sovereignty requirements, and noncompliance with medical device regulations.
The digital health market has split into two distinct tiers: a commoditising transcription layer and an enterprise agentic workflow layer.
Basic transcription and note summarisation are rapidly becoming undifferentiated background utilities. Long-term enterprise value is migrating to agentic platforms capable of closing the operational loop, reading from and writing directly to the EHR, staging diagnostic and therapeutic orders, navigating clinical coding pathways, and coordinating care across institutional boundaries.
This strategic realignment is demonstrated by capital allocation trends across the sector. In June 2025, Paris-based Nabla raised a $70 million Series C funding round (bringing its total capital raised to $120 million) specifically to finance its transition from ambient documentation to agentic clinical automation.
Nabla’s Context-Aware Agent platform is designed to leverage historical patient records to execute direct EHR commands and initiate clinical orders across extensive health networks.
Similarly, platforms such as Corti in Denmark and TORTUS in the UK have focused development on deep workflow integrations with enterprise EHR providers like Epic and Cerner, recognising that healthcare systems prioritise deep clinical interoperability over standalone transcription tools.
Enterprise Dimension | Unregulated / Class I Ambient Scribe | Certified Class IIa Agentic Workflow Platform |
Capital Allocation Focus | Sales and marketing; basic prompt engineering on third-party foundational models. | Longitudinal clinical trials, ISO 13485 QMS maintenance, Notified Body audits, and PCCP validation. |
Procurement Eligibility | Disqualified under NHS DTAC v2, ICB clinical governance, and EU MDR hospital purchasing policies. | Fully eligible; approved for enterprise-wide hospital deployments and multi-year regional framework contracts. |
EHR Integration Depth | Superficial; browser extensions, clipboard scraping, or unidirectional text pasture. | Deep, certified bidirectional integration via native Epic App Market and Oracle Cerner Millennium FHIR APIs. |
Pricing Power and Defensibility | Declining; exposed to price compression from generic LLM APIs and bundled EHR features. | High; enterprise subscription pricing tied to capacity creation, clinical throughput, and administrative hours saved. |
M&A Strategic Value | Low; vulnerable to displacement by foundational model upgrades and native EHR updates. | High; highly attractive acquisition target for legacy EHR vendors and global medtech conglomerates seeking certified action engines. |
The regulatory requirements that early-stage software companies historically avoided have inverted into an effective competitive moat.
The expense and procedural complexity of achieving Class IIa certification under EU MDR and UKCA, requiring 18 to 24 months of Notified Body assessment, audited quality management systems, published clinical evaluations, and structured post-market surveillance, create substantial barriers to entry.
Early entrants that complete this regulatory journey, secure DCB0129 compliance, and establish active PCCP structures gain a multi-year head start over fast-following competitors.
In European digital health, regulatory approval is no longer a bureaucratic hurdle; it is the core intellectual property asset protecting enterprise cash flows.
Strategic Outlook: The 2027 Certification Horizon
The clinical documentation sector in Europe is moving toward a defined milestone: in 2027, the market will witness the first formal Class IIa medical device certification (under UKCA and EU MDR) of an agentic clinical product capable of autonomously placing clinical orders and executing EHR workflows rather than drafting notes for passive review.
This milestone is supported by several converging regulatory and clinical policy developments taking place between 2026 and 2027:
The MHRA’s publication of formal AI Adaptation Guidance in December 2026, establishing a recognised regulatory pathway for Predetermined Change Control Plans (PCCPs).
The delivery of the UK Government’s implementation roadmap in Spring 2027, introducing secondary legislation to update UK MDR classification rules and formalise staged market authorisation ("L-plate") pathways for supervised NHS clinical deployment.
The operational expansion of MHRA AI Airlock Phase 3, which is actively testing post-market surveillance methodologies and multi-agent clinical lifecycle monitoring across NHS hospitals through 2029.
Pan-European regulatory enforcement following the Swedish Medical Products Agency’s May 2026 precedent, which eliminated the Class I loophole and established Class IIa under Rule 11 as the mandatory legal baseline for clinical documentation AI.
The enforcement of the EU AI Act’s high-risk conformity regime in August 2026, requiring medical software vendors to incorporate rigorous data governance, algorithmic bias monitoring, and automated event logging directly into their MDR Technical Documentation.
The debates of 2027 will redefine clinical computing and digital health investing across Europe. As simple documentation tools are absorbed into basic operating systems, commercial leadership will belong to agentic platforms that integrate bidirectional EHR execution with certified clinical safety frameworks.
By treating medical device regulation, PCCP lifecycle governance, and clinical safety engineering as core architectural components rather than administrative friction, these vanguard systems will bridge the gap between ambient listening and trusted, autonomous clinical action.
Actionable Recommendations for Key Stakeholders
MedTech innovators and AI developers must immediately abandon the Class I self certification model and the legal defence that human clinician sign-off exempts software from medical device classification. Product development strategies must align directly with EU MDR Rule 11, sub-rule 11(a) and UK MDR Class IIa standards.
Internal ISO 14971 risk registers must be audited to ensure that identified failure pathways, such as misheard clinical terms or hallucinated assertions, match external intended-use documentation.
Furthermore, engineering teams should design model retraining and fine tuning pipelines within explicit, parameter bounded envelopes that anticipate the MHRA's December 2026 PCCP guidance, allowing iterative algorithmic updates to proceed without triggering repeated pre-market reviews.
User interfaces should incorporate tiered agency frameworks, allowing routine administrative documentation to proceed autonomously while mandating deliberate, authenticated clinician sign off for high risk clinical actions to counteract automation bias.
Finally, developers must appoint an accredited Clinical Safety Officer early in the engineering lifecycle and treat the DCB0129 Hazard Log as an active technical asset integrated directly into continuous integration and continuous deployment (CI/CD) pipelines.
Healthcare providers, hospital leadership, and NHS Integrated Care Boards must establish rigorous clinical governance protocols before deploying agentic AI systems. Deploying organisations must enforce independent DCB0160 safety assessments for every clinical department utilising agentic tools, ensuring that local Clinical Safety Officers evaluate site-specific workflows rather than relying solely on vendor DCB0129 documentation.
Hospital IT departments should audit all bidirectional EHR integrations for transactional integrity, verifying that FHIR APIs support idempotent transactions and automated rollback alerts so that network timeouts cannot result in dropped orders or uncommitted encounter notes.
Additionally, healthcare providers should establish continuous post market surveillance systems in alignment with the MHRA AI Airlock Phase 3 framework, systematically tracking algorithmic drift, hallucination rates and unexpected clinical order patterns across routine care delivery.
Healthcare venture capital and private equity investors must update their underwriting models to reflect the new regulatory reality of European clinical AI. Applying horizontal SaaS metrics to clinical software is no longer appropriate; instead, investors must recognise that capital allocated toward ISO 13485 certification, Notified Body Class IIa CE marking, UKCA registration and DCB0129 compliance forms the primary enterprise moat protecting portfolio companies from commoditisation.
Investment portfolios should be systematically rebalanced away from pure-play transcription scribes and toward the agentic workflow layer, prioritising software platforms that feature verified bidirectional EHR write capabilities, active CPOE execution, and published clinical validation across multiple specialties.
Finally, investment due diligence must include forensic audits of target companies' Technical Documentation, verified intended-use claims, and ISO 14971 hazard logs to confirm that their regulatory classifications are defensible under the Swedish MPA precedent and compliant with the high-risk requirements of the EU AI Act.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Healthcare.Digital serves as a research platform for Nelson Advisors’ perspectives on deals, valuations and structural shifts reshaping Global Digital Health, MedTech, Healthcare AI and Health IT. https://www.healthcare.digital
Nelson Advisors is one of Europe's leading mergers and acquisitions advisory firms, exclusively dedicated to the dynamic and rapidly evolving healthcare technology sector. With a deep understanding of market dynamics and technological advancements, they empower innovative HealthTech companies and strategic investors to navigate complex transactions and achieve their growth ambitions. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #Genomics
Nelson Advisors
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments